Abstract
The human adult skeletal system is comprised of 206 bones, along with a network of ligaments, tendons and cartilage. In addition to providing locomotion, the skeletal tissues serve as attachment sites for muscles and as protection for vital soft tissue organs. They harbor hematopoietic tissues (bone marrow) and act as a reservoir for calcium and phosphorus. Just as with any other organ systems, many pathological conditions are associated with musculoskeletal tissues, such as osteoporosis, arthritis, impaired fracture healing, and bone cancers, etc. These diseases affect many people, especially the geriatric population, resulting in pain, stiffness, loss of body function and even mortality. The health-related quality of life in patients with musculoskeletal diseases is significantly reduced, and the rising number of patients suffering from age-related musculoskeletal diseases can become a significant economic burden in an aging society.
To address this issue, many clinical interventions, ranging from new therapeutic treatments to novel surgical procedures, have been developed. Due to the inherent nature of the musculoskeletal system and its clinical relevance, extensive work has been done in the development of nanomaterials scaffolding and the local delivery of functional agents to improve bone repair/regeneration, osseointegration with orthopedic implants and prevention or treatment of postoperative infections. This is a rather crowded field with many high quality reviews being published (Tran and Webster. Wiley Interdiscip Rev Nanomed Nanobiotechnol 1(3): 336–351, 2009; Harvey et al. J Orthop Trauma 24(Suppl 1): S25–S30, 2010; Stylios et al. Injury 38(Suppl 1): S63–S74, 2007; Sato and Webster. Expert Rev Med Devices 1(1): 105–114, 2004; Webster and Ahn. Adv Biochem Eng Biotechnol 103: 275–308, 2007), which the readers are encouraged to explore. This chapter, however, will be mainly focused on several new directions in the field, especially on the use of nanomaterials as carriers to target therapeutic agents to the musculoskeletal lesions after systemic administration. In contrast to the local nanomaterial depot approach, of which the material design and drug release/activation are somewhat arbitrary, the systemically administered carriers would “seek out” its target and deliver the drugs according to the pathological conditions present.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Boskey AL, Posner AS (1984) Bone structure, composition, and mineralization. Orthop Clin North Am 15(4):597–612
Shea JE, Miller SC (2005) Skeletal function and structure: implications for tissue-targeted therapeutics. Adv Drug Deliv Rev 57(7):945–957
Harvey EJ, Henderson JE, Vengallatore ST (2010) Nanotechnology and bone healing. J Orthop Trauma 24(Suppl 1):S25–S30
Clarke B (2008) Normal bone anatomy and physiology. Clin J Am Soc Nephrol 3(Suppl 3):S131–S139
Hadjidakis DJ, Androulakis II (2006) Bone remodeling. Ann N Y Acad Sci 1092:385–396
Feng X, McDonald JM (2011) Disorders of bone remodeling. Annu Rev Pathol 6:121–145
Boyle WJ, Simonet WS, Lacey DL (2003) Osteoclast differentiation and activation. Nature 423(6937):337–342
Silver IA, Murrills RJ, Etherington DJ (1988) Microelectrode studies on the acid microenvironment beneath adherent macrophages and osteoclasts. Exp Cell Res 175(2):266–276
Delaisse JM et al (2003) Matrix metalloproteinases (MMP) and cathepsin K contribute differently to osteoclastic activities. Microsc Res Tech 61(6):504–513
Anderson HC (2003) Matrix vesicles and calcification. Curr Rheumatol Rep 5(3):222–226
Boyce BF, Xing L (2007) The RANKL/RANK/OPG pathway. Curr Osteoporos Rep 5(3):98–104
Boyce BF, Xing L (2007) Biology of RANK, RANKL, and osteoprotegerin. Arthritis Res Ther 9(Suppl 1):S1
Boyce BF, Xing L (2008) Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch Biochem Biophys 473(2):139–146
Takada J (2006) Application of anti-resorptive drugs for the treatment of osteoporosis. Nihon Rinsho 64(2):385–391
Stepan JJ et al (2003) Mechanisms of action of antiresorptive therapies of postmenopausal osteoporosis. Endocr Regul 37(4):225–238
Honig S, Rajapakse CS, Chang G (2013) Current treatment approaches to osteoporosis - 2013. Bull Hosp Jt Dis 71(3):184–188
Blahos J (2011) Current and future options for treatment of osteoporosis. Vnitr Lek 57(11):888–890
Baron R, Hesse E (2012) Update on bone anabolics in osteoporosis treatment: rationale, current status, and perspectives. J Clin Endocrinol Metab 97(2):311–325
Donahue KE et al (2012) Drug therapy for rheumatoid arthritis in adults: an update. Agency for Healthcare Research and Quality, Rockville, MD
John M (2007) Drug therapy for rheumatoid arthritis: comparative effectiveness. In: Comparative effectiveness review summary guides for clinicians. Agency for Healthcare Research and Quality, Rockville, MD
Lima AL et al (2014) Recommendations for the treatment of osteomyelitis. Braz J Infect Dis 18:526
Tran N, Webster TJ (2009) Nanotechnology for bone materials. Wiley Interdiscip Rev Nanomed Nanobiotechnol 1(3):336–351
Stylios G, Wan T, Giannoudis P (2007) Present status and future potential of enhancing bone healing using nanotechnology. Injury 38(Suppl 1):S63–S74
Sato M, Webster TJ (2004) Nanobiotechnology: implications for the future of nanotechnology in orthopedic applications. Expert Rev Med Devices 1(1):105–114
Webster TJ, Ahn ES (2007) Nanostructured biomaterials for tissue engineering bone. Adv Biochem Eng Biotechnol 103:275–308
Choy EH et al (2005) A two year randomised controlled trial of intramuscular depot steroids in patients with established rheumatoid arthritis who have shown an incomplete response to disease modifying antirheumatic drugs. Ann Rheum Dis 64(9):1288–1293
Ruggiero SL et al (2004) Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 62(5):527–534
McHorney CA et al (2007) The impact of osteoporosis medication beliefs and side-effect experiences on non-adherence to oral bisphosphonates. Curr Med Res Opin 23(12):3137–3152
Uzawa T et al (1995) Comparison of the effects of intermittent and continuous administration of human parathyroid hormone(1-34) on rat bone. Bone 16(4):477–484
Lotinun S, Sibonga JD, Turner RT (2002) Differential effects of intermittent and continuous administration of parathyroid hormone on bone histomorphometry and gene expression. Endocrine 17(1):29–36
de Ligny CL et al (1990) Bone seeking pharmaceuticals. Int J Rad Appl Instrum B 17(2):161–179
Lin JH (1996) Bisphosphonates: a review of their pharmacokinetic properties. Bone 18(2):75–85
Hengst V et al (2007) Bone targeting potential of bisphosphonate-targeted liposomes. Preparation, characterization and hydroxyapatite binding in vitro. Int J Pharm 331(2):224–227
El-Mabhouh AA et al (2011) A conjugate of gemcitabine with bisphosphonate (Gem/BP) shows potential as a targeted bone-specific therapeutic agent in an animal model of human breast cancer bone metastases. Oncol Res 19(6):287–295
El-Mabhouh AA, Mercer JR (2008) 188Re-labelled gemcitabine/bisphosphonate (Gem/BP): a multi-functional, bone-specific agent as a potential treatment for bone metastases. Eur J Nucl Med Mol Imaging 35(7):1240–1248
El-Mabhouh AA et al (2006) A 99mTc-labeled gemcitabine bisphosphonate drug conjugate as a probe to assess the potential for targeted chemotherapy of metastatic bone cancer. Nucl Med Biol 33(6):715–722
Allen MR, Ruggiero SL (2014) A review of pharmaceutical agents and oral bone health: how osteonecrosis of the jaw has affected the field. Int J Oral Maxillofac Implants 29(1):e45–e57
Ryan P, Saleh I, Stassen LF (2009) Osteonecrosis of the jaw: a rare and devastating side effect of bisphosphonates. Postgrad Med J 85(1010):674–677
Kasugai S et al (2000) Selective drug delivery system to bone: small peptide (Asp)6 conjugation. J Bone Miner Res 15(5):936–943
Takahashi-Nishioka T et al (2008) Targeted drug delivery to bone: pharmacokinetic and pharmacological properties of acidic oligopeptide-tagged drugs. Curr Drug Discov Technol 5(1):39–48
Sekido T et al (2001) Novel drug delivery system to bone using acidic oligopeptide: pharmacokinetic characteristics and pharmacological potential. J Drug Target 9(2):111–121
Takahashi T et al (2008) Bone-targeting of quinolones conjugated with an acidic oligopeptide. Pharm Res 25(12):2881–2888
Nishioka T et al (2006) Enhancement of drug delivery to bone: characterization of human tissue-nonspecific alkaline phosphatase tagged with an acidic oligopeptide. Mol Genet Metab 88(3):244–255
Pierce WM Jr, Waite LC (1987) Bone-targeted carbonic anhydrase inhibitors: effect of a proinhibitor on bone resorption in vitro. Proc Soc Exp Biol Med 186(1):96–102
Neale JR et al (2009) Bone selective effect of an estradiol conjugate with a novel tetracycline-derived bone-targeting agent. Bioorg Med Chem Lett 19(3):680–683
Thompson WJ, Thompson DD, Anderson PS, Rodan GA (1989) Polymalonic acids as boneaffinity agents. EP 0341961
Shimoda Y et al (1994) Calcium ion binding of three different types of oligo/polysialic acids as studied by equilibrium dialysis and circular dichroic methods. Biochemistry 33(5):1202–1208
Segal E et al (2009) Targeting angiogenesis-dependent calcified neoplasms using combined polymer therapeutics. PLoS One 4(4):e5233
Choi SW, Kim JH (2007) Design of surface-modified poly(D, L-lactide-co-glycolide) nanoparticles for targeted drug delivery to bone. J Control Release 122(1):24–30
Pan H et al (2006) Water-soluble HPMA copolymer--prostaglandin E1 conjugates containing a cathepsin K sensitive spacer. J Drug Target 14(6):425–435
Henson PM (2005) Dampening inflammation. Nat Immunol 6(12):1179–1181
Yuan F et al (2012) Development of macromolecular prodrug for rheumatoid arthritis. Adv Drug Deliv Rev 64(12):1205–1219
Ren K et al (2014) Early diagnosis of orthopedic implant failure using macromolecular imaging agents. Pharm Res 31:2086
Purdue PE et al (2013) Development of polymeric nanocarrier system for early detection and targeted therapeutic treatment of peri-implant osteolysis. HSS J 9(1):79–85
Ren K et al (2014) Macromolecular prodrug of dexamethasone prevents particle-induced peri-implant osteolysis with reduced systemic side effects. J Control Release 175:1–9
Centers for Disease Control and Prevention (2009) Prevalence and most common causes of disability among adults—United States, 2005. MMWR Morb Mortal Wkly Rep 58:421–426
Quan LD et al (2008) The development of novel therapies for rheumatoid arthritis. Expert Opin Ther Pat 18(7):723–738
Tarner IH, Muller-Ladner U (2008) Drug delivery systems for the treatment of rheumatoid arthritis. Expert Opin Drug Deliv 5(9):1027–1037
Metselaar JM et al (2003) Complete remission of experimental arthritis by joint targeting of glucocorticoids with long-circulating liposomes. Arthritis Rheum 48(7):2059–2066
Khoury M et al (2006) Efficient new cationic liposome formulation for systemic delivery of small interfering RNA silencing tumor necrosis factor alpha in experimental arthritis. Arthritis Rheum 54(6):1867–1877
Koning GA et al (2006) Targeting of angiogenic endothelial cells at sites of inflammation by dexamethasone phosphate-containing RGD peptide liposomes inhibits experimental arthritis. Arthritis Rheum 54(4):1198–1208
Gaspar MM et al (2007) Enzymosomes with surface-exposed superoxide dismutase: in vivo behaviour and therapeutic activity in a model of adjuvant arthritis. J Control Release 117(2):186–195
Kapoor B et al (2014) Application of liposomes in treatment of rheumatoid arthritis: quo vadis. ScientificWorldJournal 2014:978351
Vanniasinghe AS, Bender V, Manolios N (2009) The potential of liposomal drug delivery for the treatment of inflammatory arthritis. Semin Arthritis Rheum 39(3):182–196
van den Hoven JM et al (2011) Liposomal drug formulations in the treatment of rheumatoid arthritis. Mol Pharm 8(4):1002–1015
Metselaar JM et al (2004) Liposomal targeting of glucocorticoids to synovial lining cells strongly increases therapeutic benefit in collagen type II arthritis. Ann Rheum Dis 63(4):348–353
Avnir Y et al (2008) Amphipathic weak acid glucocorticoid prodrugs remote-loaded into sterically stabilized nanoliposomes evaluated in arthritic rats and in a Beagle dog: a novel approach to treating autoimmune arthritis. Arthritis Rheum 58(1):119–129
Danhier F et al (2012) PLGA-based nanoparticles: an overview of biomedical applications. J Control Release 161(2):505–522
Higaki M et al (2005) Treatment of experimental arthritis with poly(D, L-lactic/glycolic acid) nanoparticles encapsulating betamethasone sodium phosphate. Ann Rheum Dis 64(8):1132–1136
Ishihara T et al (2009) Treatment of experimental arthritis with stealth-type polymeric nanoparticles encapsulating betamethasone phosphate. J Pharmacol Exp Ther 329(2):412–417
Crielaard BJ et al (2012) Glucocorticoid-loaded core-cross-linked polymeric micelles with tailorable release kinetics for targeted therapy of rheumatoid arthritis. Angew Chem Int Ed Engl 51(29):7254–7258
Wilson DR et al (2014) Synthesis and evaluation of cyclosporine A-loaded polysialic acid-polycaprolactone micelles for rheumatoid arthritis. Eur J Pharm Sci 51:146–156
Quan L et al (2014) Nanomedicines for inflammatory arthritis: head-to-head comparison of glucocorticoid-containing polymers, micelles, and liposomes. ACS Nano 8(1):458–466
Liu XM et al (2008) Synthesis and evaluation of a well-defined HPMA copolymer-dexamethasone conjugate for effective treatment of rheumatoid arthritis. Pharm Res 25(12):2910–2919
Quan LD et al (2010) Development of a macromolecular prodrug for the treatment of inflammatory arthritis: mechanisms involved in arthrotropism and sustained therapeutic efficacy. Arthritis Res Ther 12(5):R170
Liu XM et al (2010) Syntheses of click PEG-dexamethasone conjugates for the treatment of rheumatoid arthritis. Biomacromolecules 11(10):2621–2628
Wang D et al (2002) Inhibition of cathepsin K with lysosomotropic macromolecular inhibitors. Biochemistry 41(28):8849–8859
Lawrence RC et al (2008) Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum 58(1):26–35
Felson DT (2014) Osteoarthritis: priorities for osteoarthritis research: much to be done. Nat Rev Rheumatol 10:447
Gerwin N, Hops C, Lucke A (2006) Intraarticular drug delivery in osteoarthritis. Adv Drug Deliv Rev 58(2):226–242
Hinton R et al (2002) Osteoarthritis: diagnosis and therapeutic considerations. Am Fam Physician 65(5):841–848
Hochberg MC et al (1995) Guidelines for the medical management of osteoarthritis. Part II. Osteoarthritis of the knee. American College of Rheumatology. Arthritis Rheum 38(11):1541–1546
George E (1998) Intra-articular hyaluronan treatment for osteoarthritis. Ann Rheum Dis 57(11):637–640
Dingle JT et al (1978) Novel treatment for joint inflammation. Nature 271(5643):372–373
Foong WC, Green KL (1988) Retention and distribution of liposome-entrapped [3H]methotrexate injected into normal or arthritic rabbit joints. J Pharm Pharmacol 40(7):464–468
Holland TA, Mikos AG (2003) Advances in drug delivery for articular cartilage. J Control Release 86(1):1–14
Ratcliffe JH et al (1987) Albumin microspheres for intra-articular drug delivery: investigation of their retention in normal and arthritic knee joints of rabbits. J Pharm Pharmacol 39(4):290–295
Horisawa E et al (2002) Prolonged anti-inflammatory action of DL-lactide/glycolide copolymer nanospheres containing betamethasone sodium phosphate for an intra-articular delivery system in antigen-induced arthritic rabbit. Pharm Res 19(4):403–410
Brown KE et al (1998) Gelatin/chondroitin 6-sulfate microspheres for the delivery of therapeutic proteins to the joint. Arthritis Rheum 41(12):2185–2195
Iwasaki M, Soh M, Kaneko H (1991) Diagnosis, treatment and prophylaxis of catheter related sepsis. Nihon Rinsho 49(Suppl):182–187
Holroyd C, Cooper C, Dennison E (2008) Epidemiology of osteoporosis. Best Pract Res Clin Endocrinol Metab 22(5):671–685
Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A (2007) Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025. J Bone Miner Res 22:465–475
Cenni E et al (2008) Biocompatibility of poly(D, L-lactide-co-glycolide) nanoparticles conjugated with alendronate. Biomaterials 29(10):1400–1411
Pignatello R et al (2009) A novel biomaterial for osteotropic drug nanocarriers: synthesis and biocompatibility evaluation of a PLGA-ALE conjugate. Nanomedicine (Lond) 4(2):161–175
Wang D et al (2006) Pharmacokinetic and biodistribution studies of a bone-targeting drug delivery system based on N-(2-hydroxypropyl)methacrylamide copolymers. Mol Pharm 3(6):717–725
Zhang G et al (2012) A delivery system targeting bone formation surfaces to facilitate RNAi-based anabolic therapy. Nat Med 18(2):307–314
Sang Yoo H, Gwan Park T (2004) Biodegradable nanoparticles containing protein-fatty acid complexes for oral delivery of salmon calcitonin. J Pharm Sci 93(2):488–495
Narayanan D et al (2013) In vitro and in vivo evaluation of osteoporosis therapeutic peptide PTH 1-34 loaded PEGylated chitosan nanoparticles. Mol Pharm 10(11):4159–4167
Takeuchi H et al (2003) Mucoadhesive properties of carbopol or chitosan-coated liposomes and their effectiveness in the oral administration of calcitonin to rats. J Control Release 86(2-3):235–242
Lamprecht A et al (2004) pH-sensitive microsphere delivery increases oral bioavailability of calcitonin. J Control Release 98(1):1–9
Narayanan D et al (2014) PTH 1-34 loaded thiolated chitosan nanoparticles for osteoporosis: oral bioavailability and anabolic effect on primary osteoblast cells. J Biomed Nanotechnol 10(1):166–178
Saini D, Fazil M, Ali MM, Baboota S, Ali J (2015) Formulation, development and optimization of raloxifeneloaded chitosan nanoparticles for treatment of osteoporosis. Drug Deliv 22:1–14. [Epub ahead of print]
Fazil M et al (2013) Exploring drug delivery systems for treating osteoporosis. Expert Opin Drug Deliv 10(8):1123–1136
Low SA, Kopecek J (2012) Targeting polymer therapeutics to bone. Adv Drug Deliv Rev 64(12):1189–1204
Society AC (2008) Cancer facts and figures 2008. American Cancer Society. Retrieved on March 13, 2008
Hughes DP (2009) Strategies for the targeted delivery of therapeutics for osteosarcoma. Expert Opin Drug Deliv 6(12):1311–1321
Gabizon A, Martin F (1997) Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours. Drugs 54(Suppl 4):15–21
Alberts DS, Garcia DJ (1997) Safety aspects of pegylated liposomal doxorubicin in patients with cancer. Drugs 54(Suppl 4):30–35
Skubitz KM (2003) Phase II trial of pegylated-liposomal doxorubicin (Doxil) in sarcoma. Cancer Invest 21(2):167–176
Judson I et al (2001) Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 37(7):870–877
Kamba SA et al (2013) In vitro delivery and controlled release of Doxorubicin for targeting osteosarcoma bone cancer. Molecules 18(9):10580–10598
Susa M et al (2009) Doxorubicin loaded Polymeric Nanoparticulate Delivery System to overcome drug resistance in osteosarcoma. BMC Cancer 9:399
Federman N et al (2012) Enhanced growth inhibition of osteosarcoma by cytotoxic polymerized liposomal nanoparticles targeting the alcam cell surface receptor. Sarcoma 2012:126906
Coleman RE (2006) Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 12(20 Pt 2):6243s–6249s
Guise T (2010) Examining the metastatic niche: targeting the microenvironment. Semin Oncol 37(Suppl 2):S2–S14
Clezardin P, Benzaid I, Croucher PI (2011) Bisphosphonates in preclinical bone oncology. Bone 49(1):66–70
Coleman R (2011) The use of bisphosphonates in cancer treatment. Ann N Y Acad Sci 1218:3–14
Gnant M (2009) Bisphosphonates in the prevention of disease recurrence: current results and ongoing trials. Curr Cancer Drug Targets 9(7):824–833
Coleman RE, McCloskey EV (2011) Bisphosphonates in oncology. Bone 49(1):71–76
Ramanlal Chaudhari K et al (2012) Bone metastasis targeting: a novel approach to reach bone using Zoledronate anchored PLGA nanoparticle as carrier system loaded with Docetaxel. J Control Release 158(3):470–478
Miller K et al (2009) Targeting bone metastases with a bispecific anticancer and antiangiogenic polymer-alendronate-taxane conjugate. Angew Chem Int Ed Engl 48(16):2949–2954
Miller K et al (2011) Antiangiogenic antitumor activity of HPMA copolymer-paclitaxel-alendronate conjugate on breast cancer bone metastasis mouse model. Mol Pharm 8(4):1052–1062
Daubine F et al (2009) Nanostructured polyelectrolyte multilayer drug delivery systems for bone metastasis prevention. Biomaterials 30(31):6367–6373
Wang D et al (2007) Osteotropic Peptide that differentiates functional domains of the skeleton. Bioconjug Chem 18(5):1375–1378
Gogia JS et al (2009) Local antibiotic therapy in osteomyelitis. Semin Plast Surg 23(2):100–107
Diana Gomes MP, Bettencourt AF (2013) Osteomyelitis: an overview of antimicrobial therapy. Braz J Pharm Sci 49(1):13–27
Verhelle N et al (2003) How to deal with bone exposure and osteomyelitis: an overview. Acta Orthop Belg 69(6):481–494
Lang S (1996) Osteomyelitis. A pathomorphologic overview. Radiologe 36(10):781–785
Mouzopoulos G et al (2011) Management of bone infections in adults: the surgeon’s and microbiologist’s perspectives. Injury 42(Suppl 5):S18–S23
Kanellakopoulou K, Giamarellos-Bourboulis EJ (2000) Carrier systems for the local delivery of antibiotics in bone infections. Drugs 59(6):1223–1232
Holtom PD, Patzakis MJ (2003) Newer methods of antimicrobial delivery for bone and joint infections. Instr Course Lect 52:745–749
Nelson CL et al (1992) In vitro elution characteristics of commercially and noncommercially prepared antibiotic PMMA beads. Clin Orthop Relat Res 284:303–309
Mader JT, Calhoun J, Cobos J (1997) In vitro evaluation of antibiotic diffusion from antibiotic-impregnated biodegradable beads and polymethylmethacrylate beads. Antimicrob Agents Chemother 41(2):415–418
Gitelis S, Brebach GT (2002) The treatment of chronic osteomyelitis with a biodegradable antibiotic-impregnated implant. J Orthop Surg (Hong Kong) 10(1):53–60
Desai TA, Uskokovic V (2013) Calcium phosphate nanoparticles: a future therapeutic platform for the treatment of osteomyelitis? Ther Deliv 4(6):643–645
Singh N et al (2009) NanoGenotoxicology: the DNA damaging potential of engineered nanomaterials. Biomaterials 30(23-24):3891–3914
Uskokovic V, Desai TA (2013) Phase composition control of calcium phosphate nanoparticles for tunable drug delivery kinetics and treatment of osteomyelitis. II. Antibacterial and osteoblastic response. J Biomed Mater Res A 101(5):1427–1436
Uskokovic V, Desai TA (2013) Phase composition control of calcium phosphate nanoparticles for tunable drug delivery kinetics and treatment of osteomyelitis. I. Preparation and drug release. J Biomed Mater Res A 101(5):1416–1426
Uskokovic V et al (2013) Effect of calcium phosphate particle shape and size on their antibacterial and osteogenic activity in the delivery of antibiotics in vitro. ACS Appl Mater Interfaces 5(7):2422–2431
Uskokovic V et al (2013) Osteogenic and antimicrobial nanoparticulate calcium phosphate and poly-(D, L-lactide-co-glycolide) powders for the treatment of osteomyelitis. Mater Sci Eng C Mater Biol Appl 33(6):3362–3373
Fang T et al (2012) Poly (epsilon-caprolactone) coating delays vancomycin delivery from porous chitosan/beta-tricalcium phosphate composites. J Biomed Mater Res B Appl Biomater 100(7):1803–1811
Samit Kumar Nandi PM, Roy S, Kundu B, De Kumar D, Basu D (2009) Local antibiotic delivery systems for the treatment of osteomyelitis – a review. Mater Sci Eng C 29(8):2478–2485
Oldham JB et al (2000) Biological activity of rhBMP-2 released from PLGA microspheres. J Biomech Eng 122(3):289–292
Cao L et al (2014) Vascularization and bone regeneration in a critical sized defect using 2-N,6-O-sulfated chitosan nanoparticles incorporating BMP-2. Biomaterials 35(2):684–698
Raftery R, O’Brien FJ, Cryan SA (2013) Chitosan for gene delivery and orthopedic tissue engineering applications. Molecules 18(5):5611–5647
Gentile P et al (2014) An overview of poly(lactic-co-glycolic) acid (PLGA)-based biomaterials for bone tissue engineering. Int J Mol Sci 15(3):3640–3659
Puppi D et al (2011) Optimized electro- and wet-spinning techniques for the production of polymeric fibrous scaffolds loaded with bisphosphonate and hydroxyapatite. J Tissue Eng Regen Med 5(4):253–263
Nie H, Wang CH (2007) Fabrication and characterization of PLGA/HAp composite scaffolds for delivery of BMP-2 plasmid DNA. J Control Release 120(1-2):111–121
Mouthuy PA et al (2010) Physico-chemical characterization of functional electrospun scaffolds for bone and cartilage tissue engineering. Proc Inst Mech Eng H 224(12):1401–1414
Lin G et al (2012) Injectable and thermosensitive PLGA-g-PEG hydrogels containing hydroxyapatite: preparation, characterization and in vitro release behavior. Biomed Mater 7(2):024107
Lee TJ et al (2010) Apatite-coated porous poly(lactic-co-glycolic acid) microspheres as an injectable bone substitute. J Biomater Sci Polym Ed 21(5):635–645
Shi X et al (2009) Enhancing alendronate release from a novel PLGA/hydroxyapatite microspheric system for bone repairing applications. Pharm Res 26(2):422–430
Wang Q et al (2013) Hybrid hydroxyapatite nanoparticle colloidal gels are injectable fillers for bone tissue engineering. Tissue Eng Part A 19(23-24):2586–2593
Yao Y, Shi X, Chen F (2014) The effect of gold nanoparticles on the proliferation and differentiation of murine osteoblast: a study of MC3T3-E1 cells in vitro. J Nanosci Nanotechnol 14(7):4851–4857
Rose FR, Hou Q, Oreffo RO (2004) Delivery systems for bone growth factors - the new players in skeletal regeneration. J Pharm Pharmacol 56(4):415–427
Nguyen LT, Min YK, Lee BT (2015) Nanoparticle biphasic calcium phosphate loading on gelatin-pectin scaffold for improved bone regeneration. Tissue Eng Part A 21:1376
Hu J et al (2014) Effect of nano-hydroxyapatite coating on the osteoinductivity of porous biphasic calcium phosphate ceramics. BMC Musculoskelet Disord 15:114
Kawazoe N, Chen G, Tateishi T (2008) Development of novel biomaterials for bone and cartilage tissue engineering. Clin Calcium 18(12):1713–1720
Zhou YN, Xia LG, Xu YJ (2014) Research progress of nano-hydroxyapatite complexes in bone tissue regeneration. Shanghai Kou Qiang Yi Xue 23(2):248–252
Matassi F et al (2011) New biomaterials for bone regeneration. Clin Cases Miner Bone Metab 8(1):21–24
Perez-Sanchez MJ et al (2010) Biomaterials for bone regeneration. Med Oral Patol Oral Cir Bucal 15(3):e517–e522
Allo BA et al (2012) Bioactive and biodegradable nanocomposites and hybrid biomaterials for bone regeneration. J Funct Biomater 3(2):432–463
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer Science+Business Media New York
About this protocol
Cite this protocol
Ren, K., Wei, X., Zhang, L., Wang, D. (2016). Nanomedicine for the Treatment of Musculoskeletal Diseases. In: Lu, ZR., Sakuma, S. (eds) Nanomaterials in Pharmacology. Methods in Pharmacology and Toxicology. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-3121-7_20
Download citation
DOI: https://doi.org/10.1007/978-1-4939-3121-7_20
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-3120-0
Online ISBN: 978-1-4939-3121-7
eBook Packages: Springer Protocols